Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of FPF1011 (chenodeoxycholic acid) in cerebrotendinous xanthomatosis
jRCT2080225062Phase 3Completed
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of chenodeoxycholic acid in cerebrotendinous xanthomatosis (CTX), sponsored by Fujimoto Pharmaceutical. Primary endpoints: Serum cholestanol level reduction and Safety and tolerability. Started Feb 2020; status: completed.
02
Drugs
chenodeoxycholic acid
03
Conditions
cerebrotendinous xanthomatosis (CTX)
Beyond the preview
Go deeper on jRCT2080225062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225062.